← All trials
NCT04853407
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2018
- Primary completion
- Dec 24, 2020
- Completion date
- Dec 24, 2020
- First posted
- Apr 21, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 558
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Luye PharmaLead sponsor
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.